Jump to content

Biotech XPrize board member raises $100M fund to tackle aging


Recommended Posts


XPrize board member raises $100M fund to tackle aging

by Nick Paul Taylor | 
Feb 5, 2019 9:20am
Longevity Vision Fund founder Sergey Young (XPrize)

Longevity Vision Fund has exited stealth with plans to invest $100 million in startups with aspirations to extend healthy life spans. The fund, which is linked to the founder of XPrize, will pump the money into biotechs and other longevity startups based around the world in seed to series B rounds.


Sergey Young, the founder of Longevity Vision, unveiled the fund at an event in London this week. Young is the cofounder of Peak State Ventures and an innovation board member at XPrize Foundation, a nonprofit known for running competitions to incentivize advances in fields including suborbital space flight.

At Peak State, Young and his colleagues invest in fields well outside of longevity, including property and education. But Young has established a foothold in the longevity space, leading to him becoming development sponsor of Longevity XPrize and a longevity partner at Bold Capital Partners.

Now, Young is using his experience and connections to invest $100 million in the longevity sector. The fund will cooperate with Bold Capital, a VC fund created by XPrize founder Peter Diamandis that has backed startups in or adjacent to the longevity field such as Iota Biosciences and Insilico Medicine.

Longevity Vision will get deeper into the field by investing in startups in the U.S., China and Europe that are working on therapeutics, IT products, services and infrastructure related to the goal of increasing healthy human life spans.

Young wants to increase human life spans to 200 years and make the technologies that enable such advances available to 1 billion people or more. Some of Young’s collaborators publicly express more conservative goals, but either way the potential health and financial payoffs are significant.

“Adding 20 to 30 healthy years on a person's life is likely to be the largest market opportunity on Earth. The convergence of genome sequencing, AI and cellular medicine will enable breakthroughs that will make 100 years old the new 60,” Diamandis said in a statement.

The ability of therapeutics and other complementary technologies to power such changes in healthy life spans remains unproven, but a growing pool of investors and startups are working on the problem. For now, the sums involved remain relatively small compared to the broader biotech sector, with the $100 million Longevity Vision Fund joining Juvenescence among the bigger players.

Link to comment
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.

Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

  • Create New...